Skip to content
NeuroTechGuide

StairMed says it has 42 long-term BCI implants and has finished enrolling a registration trial

The Shanghai company also reports raising about RMB 1.4 billion since the start of the second half of 2026. The figures are company-reported, and no enrollment number or trial results were given.

1 min readImplantsClinical trialsFunding

Shanghai-based StairMed (阶梯医疗) says it has completed 42 long-term implants of its fully invasive brain-computer interface and has finished enrolling a registration trial of its WRS 01 system, according to an October 28 article on The Paper. The article calls this the first fully invasive BCI product in the world to complete enrollment in a registration trial. That claim was not independently confirmed.

What was reported

WRS 01 is a 256-channel implant with eight ultra-flexible electrode threads, intended to restore motor function in people with high-level paralysis. The article reports these figures:

  • More than 5,000 cumulative implanted days and more than 10,000 hours of BCI use across participants.
  • In a cursor test, latency under 0.05 seconds and a peak information transfer rate of 390 bits per minute.
  • Admission to the special review program for innovative devices run by China’s National Medical Products Administration, and market approval in June for a semi-automatic system used to place the electrodes.
  • About RMB 1.4 billion raised since the start of the second half of 2026, for RMB 2.6 billion in total as of September. Investors were not named.

The article compares the 42 implants with 27 publicly reported long-term implants at Neuralink. In March, StairMed said it planned registration trials of about 40 patients. That report named the 256-channel wireless system WRS02, so the relationship between the two product names is unclear.

Why it matters

A registration trial generates the evidence regulators use to decide on market approval, so finishing enrollment would put a fully invasive BCI closer to a commercial decision in China.

There are important caveats. The article gives no enrollment number, trial sites, design or outcomes, and it was published through a channel that carries content supplied by the uploading author or institution. Implant counts also say little about safety or long-term benefit until trial results are published.

Learn more: Clinical trial pathway · Microelectrode array · StairMed

Share:XLinkedInBlueskyEmail

More news